Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat and prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia in patients at risk. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (1.5 g) once daily. * **Treatment (mild hypokalemia):** 40-100 mEq (3-7.5 g) per day divided into 2-5 doses. * **Treatment (severe hypokalemia):** May require higher doses, up to 200 mEq (15 g) per day, under close monitoring. * *Maximum oral dose:* Generally not to exceed 200 mEq (15 g) per 24 hours. * **Intravenous (IV):** * **Prevention:** 10-20 mEq (0.75-1.5 g) per dose, usually added to maintenance IV fluids. * **Treatment (mild hypokalemia, serum K+ 2.5-3.5 mEq/L):** 40-60 mEq (3-4.5 g) per day, divided doses, maximum infusion rate 10-20 mEq/hour. * **Treatment (severe hypokalemia, serum K+ < 2.5 mEq/L):** May require up to 100-200 mEq (7.5-15 g) per day via central venous access. **Infusion must be slow and carefully monitored.** * *Maximum IV dose:* Generally not to exceed 20 mEq (1.5 g) per hour in peripheral lines, or 40 mEq (3 g) per hour via central line, depending on local protocol and patient tolerance. **Rapid infusion can be fatal.** ## Pediatric Dosing Dosing is highly individualized and depends on age, weight, and serum potassium levels. Consult specific pediatric protocols. * **Oral:** Typically 1-3 mEq/kg/day, divided doses. Maximum dose generally not to exceed 20 mEq/dose or 100 mEq/day. * **Intravenous (IV):** * **Prevention:** 0.5-1 mEq/kg/day, not to exceed 20 mEq/day. * **Treatment:** Dosing varies widely; often 1-2 mEq/kg per dose, with a maximum infusion rate of 0.3-0.5 mEq/kg/hour (or 10-20 mEq/hour). Higher doses and rates may be used in critical care settings with continuous cardiac monitoring. * **Concentration limits:** Maximum concentration typically 40 mEq/L in peripheral lines and 80 mEq/L in central lines to reduce phlebitis risk. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Dose reduction is necessary, and frequent monitoring of potassium and renal function is essential. In severe renal impairment, potassium supplementation may be contraindicated. * **Adrenal Insufficiency:** Patients may be more sensitive to the effects of potassium. ## Contraindications * Hyperkalemia. * Conditions that predispose to hyperkalemia (e.g., severe renal impairment, untreated Addison's disease, severe burns, crush injuries, administration of potassium-sparing diuretics). * Known hypersensitivity to the drug. * Gastrointestinal obstruction or delayed gastric emptying (for oral formulations). ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea (oral). * **Serious:** * Hyperkalemia (potentially life-threatening): Arrhythmias, muscle weakness, paresthesia, paralysis, cardiac arrest. * Gastrointestinal ulceration, bleeding, perforation (especially with sustained-release oral formulations). * Phlebitis, venous irritation, pain (IV). * Arrhythmias, cardiac arrest (with rapid IV infusion). ## Key Drug Interactions * **ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), Potassium-Sparing Diuretics (e.g., spironolactone, amiloride), Trimethoprim, NSAIDs, Heparin:** Increased risk of hyperkalemia. * **Diuretics (non-potassium sparing):** Can increase potassium loss, requiring closer monitoring. * **Digitalis Glycosides:** Hypokalemia exacerbates digitalis toxicity; hyperkalemia reduces the efficacy of digitalis. ## Monitoring * **Serum Potassium:** Frequent monitoring is crucial, especially during IV administration and dose adjustments. Frequency depends on the clinical situation and route of administration. * **Renal Function (BUN, Creatinine):** Essential, particularly in patients with impaired renal function. * **ECG:** Monitor for signs of hyperkalemia (peaked T waves, prolonged PR interval, loss of P waves, widened QRS complex). * **Urine Output:** Assess adequate renal function. * **Signs and Symptoms of Hypo/Hyperkalemia:** Muscle weakness, fatigue, palpitations, gastrointestinal distress. ## Clinical Pearls * Oral potassium chloride should be taken with meals or immediately after to minimize gastrointestinal upset and ulceration. * Liquid formulations are generally preferred over solid forms to reduce gastrointestinal irritation. * IV potassium chloride **must never be administered undiluted or as a bolus injection** due to the risk of cardiac arrest. Always dilute appropriately and infuse at recommended rates. * Always verify IV potassium concentration and infusion rate with another licensed healthcare professional. * Patients with diarrhea, vomiting, or nasogastric suction are at increased risk of hypokalemia. * Correct magnesium levels before correcting potassium, as hypomagnesemia can impair potassium repletion. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance. Dosing and recommendations may vary.*